481072-42-8

Basic information

• Product Name: 3-(4-benzyloxyphenyl)-2-hydroxypropionic acid isopropyl ester
• Synonyms: 3-(4-benzyloxyphenyl)-2-hydroxypropionic acid isopropyl ester
• CAS NO: 481072-42-8
• Molecular Weight: 314.381
• Mol File: 481072-42-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-(4-benzyloxyphenyl)-2-hydroxypropionic acid isopropyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-benzyloxyphenyl)-2-hydroxypropionic acid isopropyl ester(481072-42-8)
• EPA Substance Registry System: 3-(4-benzyloxyphenyl)-2-hydroxypropionic acid isopropyl ester(481072-42-8)

Safety Data

• Hazardous Substances Data: 481072-42-8(Hazardous Substances Data)

Upstream product

• 100-44-7 benzyl chloride 
• 23508-35-2 (S)-2-hydroxy-3-(4-hydroxy-phenyl)-propionic acid 
• 156-39-8 4-hydroxyphenylpiruvic acid 
• 67-63-0 isopropyl alcohol 
• 162919-37-1 (S)-3-[4-(benzyloxy)phenyl]-2-hydroxypropanoic acid 

Downstream Products

• 251454-49-6 (2S)-3-[4-(benzyloxy)phenyl]-2-ethoxypropanoic acid 
• 251454-50-9 ethyl (2S)-3-[4-(benzyloxy)phenyl]-2-ethoxypropanoate 
• 405271-21-8 2-ethoxy-3-(4-benzyloxyphenyl)propionic acid isopropyl ester 

Relevant articles and documents

Synthesis of a peroxime proliferator activated receptor (PPAR) α/γ agonist via stereocontrolled Williamson ether synthesis and stereospecific SN2 reaction of S-2-chloro propionic acid with phenoxides

The stereospecific synthesis of the PPAR α/γ agonist 1 was accomplished via ethylation of the optically pure trihydroxy derivative 6, itself derived via an enzymatic resolution. The ethylation can be accomplished without epimerization only under strict control of the reaction conditions and the choice of base (sodium tert-amylate), temperature (-30°C), order of addition, and solvent (DMF). The key diastereospecific SN2 reaction of the phenol 4 with S-2-chloropropionic acid is best achieved via the sodium phenoxide of 4 derived from Na0 as the reagent of choice. The structure elucidation and key purification protocols to achieve pharmaceutical purity will also be described